We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Strongyloidiasis Antibodies Found in Transplant Donors

By LabMedica International staff writers
Posted on 10 Dec 2018
Print article
Image: A histopathology of Strongyloides stercoralis in the duodenum (Photo courtesy of Dr. Raul S. Gonzalez, MD).
Image: A histopathology of Strongyloides stercoralis in the duodenum (Photo courtesy of Dr. Raul S. Gonzalez, MD).
Strongyloidiasis is a neglected tropical disease caused by a parasite, which is endemic in most parts of the world. It can cause a life-threatening disease among immunosuppressed individuals and can be transmitted from solid organ transplant (SOT) donors to recipients.

Due to the characteristic life cycle of Strongyloides stercoralis, individuals can carry the infection lifelong with mild or no symptoms, unless treated. The disease endemic in large parts of Latin America, Asia and Africa with an estimated prevalence of more than 400 million infected.

Scientists at the Universitat de Barcelona (Barcelona, Spain) carried out a retrospective study including all deceased individuals from endemic areas for strongyloidiasis who were considered for organ donation between January 2004 and December 2014 in the Hospital Clinic. During the period 2004–2014, 1,025 deceased individuals were evaluated as potential deceased organ donors. Of these, 90 donors (8.78%) were native from endemic areas for strongyloidiasis. Most were males (63/90 cases; 70%) and median age of all cases was 41 years old. More than half of the deceased organ donors from endemic areas had been born in Latin America (49/90 cases; 54.44%), whereas the rest were from Southeast Asia (24/90 cases; 26.67%) and Africa (17/90 cases; 18.89%).

The team used the serum samples of potential donors from endemic areas for strongyloidiasis, and performed a S. stercoralis serological test. The commercial test IVD-ELISA, which detects immunoglobulin G (IgG) antibodies by using somatic antigens from larvae of the parasite, was used and has a sensitivity of 91.2%, and a specificity of 99.1%. Currently, IVD-ELISA is the available test in the hospital. The sample is defined as positive if the absorbance/0.2 (i) > 1.1.

The scientists found there were only in 65 of 90 cases available serum samples and analyzed for S. stercoralis serology and 6/65 cases (9.23%) were found to have a positive test for strongyloidiasis. S. stercoralis serology indices ranged between 1.84 and 9.32. From the six positive cases, three individuals were native from Latin America (two from Brazil and one from Ecuador), two from Africa (Senegal and Ghana) and one from Southeast Asia (Philippines).

The authors concluded that they had found a high seroprevalence of strongyloidiasis in individuals from endemic settings evaluated as potential deceased donors for SOT. The data reinforce the importance of following current guidelines recommending systematic screening of potential donors from endemic areas. There is an urgent need to develop rapid diagnostic tests, which can be used in daily clinical practice. The study was published on November 29, 2018, in the journal Public Library of Science Neglected tropical Diseases.

Related Links:
Universitat de Barcelona

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
Herpes Simplex Virus ELISA
HSV 2 IgG – ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.